Skip to main content

Bisaro Paul

In the past year, 2 open-market purchase filings worth $179.4K and no sales.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
$179.4K
2 filings
Sold
–
0 filings
Net
+$179.4K
Bought minus sold
Companies
2
With open-market trades

Trades

Every Form 4 that lists Bisaro Paul as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

MYGN Myriad Genetics Inc

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 14, 2026 (view filing)May 14Same dayBisaro PaulDirectorPPurchase+7.50K$3.69+$27.7K+8.3%97.4K after

ZTS Zoetis Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 13, 2026 (view filing)May 13Same dayBisaro PaulDirectorPPurchase+2.00K$75.88+$151.8K+7.7%27.9K after

MNKTQ Keenova Therapeutics plc

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 16, 2023 (view filing)Mar 142 daysBisaro PaulDirectorPPurchase+5.00K$8.47+$42.4K+7.2%74.8K after

TXMD TherapeuticsMD, Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 18, 2021 (view filing)Aug 162 daysBisaro PaulDirectorPPurchase+50.0K$0.79+$39.5K+34.0%196.9K after